April 30, 2026
FOCUS on Pancreatic Cancer. In a paper just out in Nature Medicine, the team at Actuate Therapeutics reported the results of their Phase II trial on […]
April 17, 2026
FOCUS on New Cancer Therapeutic Targets. Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and is largely driven by metabolic disorders such as obesity […]
March 12, 2026
FOCUS on a New Pharma Success Story. Day One Biopharmaceuticals is only 8 years old, yet in that short period of time it bought the rights […]
March 4, 2026
FOCUS on new drug approvals. On February 24th the FDA granted approval to Encorafenib (Braftovi, Array Biopharma, a subsidiary of Pfizer) in combination with cetuximab and […]
February 5, 2026
FOCUS On Kinase Inhibitors. The FDA recently approved its 100th kinase inhibitor, marking a major milestone in precision medicine since its first kinase inhibitor approval (Imatinib) […]
December 23, 2025
FOCUS on Clinical Trials. Takeda has announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib […]
December 16, 2025
FOCUS on Drug Failures. Yesterday Sanofi provided an update on tolebrutinib (SAR442168, a Bruton tyrosine kinase inhibitor), in primary progressive multiple sclerosis. Results from the PERSEUS […]
November 11, 2025
FOCUS on MS Drug Development. Roche announced this week that the first of two pivotal phase III studies (FENhance 1 and 2) in patients with relapsing […]
August 16, 2025
FOCUS on Drug Approvals. On August 8 the FDA granted accelerated approval to Boehringer Ingelheim’s Zongertinib (BI 1810631) for adults with unresectable or metastatic non-squamous non-small […]